

O 11 SCITA
JUN 05 2002
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Attorney Docket No. 018781006810

PTO/SB/96 (08-00)
Approved as through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Attorney Docket No. 018781006810

RECEIVED

AUG 26 2002

CENTER 1600/2900

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Scott Powers, David Mu, Phil Xiang and Yue Peng

Application No./Patent No.: 10/041,030

Filed/Issue Date: December 28, 2001

Entitled: DIAGNOSIS AND TREATMENT OF CANCER USING MAMMALIAN PELLINO POLYPEPTIDES AND POLYNUCLEOTIDES

Tularik Inc.

(Name of Assignee)

a Delaware corporation
(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- the assignee of the entire right, title, and interest; or
- an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.


Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

3/20/02

Date



Signature

Christopher J. Smith

Typed or printed name

Director, Intellectual Property

Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ASSIGNMENT OF PATENT APPLICATION

JOINT

WHEREAS, Scott Powers of 6 Westbrook Court, Greenlawn, NY 11740; David Mu of 84 Rockland Drive, Jericho, NY 11753; Phil Xiang of 530 Vidal Drive, San Francisco, CA 94132; and Yue Peng of 5 Hattie Lane, South Setauket, NY 11720; hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below-identified application for United States Letters Patent:

Title of Invention: **DIAGNOSIS AND TREATMENT OF CANCER USING
MAMMALIAN PELLINO POLYPEPTIDES AND
POLYNUCLEOTIDES**

Date(s) of execution of Declaration: **3/18/02, 3/20/02**

Filing Date: **December 28, 2001**

Application No.: **10/041,030; and**

WHEREAS, Tularik Inc., a corporation of the state of Delaware, located at Two Corporate Drive, South San Francisco, CA, 94080, hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.


Assignors further agree that they will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

Assignors hereby authorize and request Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834, to insert herein above the application number and filing date of said application when known.

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Assignment
Attorney Docket No.: 018781-006810US
Page 2

Dated: March 20 2002


Scott Powers

Scott Powers


WITNESS


Christina Marandino
WITNESS

Dated: 3/20/02



David Mu


WITNESS


Christina Marandino
WITNESS

Dated: _____


Phil Xiang


WITNESS


WITNESS

Dated: 3/20/02


Yue Peng


Christina Marandino
WITNESS


WITNESS

Assignment
Attorney Docket No.: 018781-006810US
Page 2

Dated: _____

Scott Powers

WITNESS

WITNESS

Dated: _____

David Mu

WITNESS

WITNESS

Dated: 3/18/02

Phil Xiang

WITNESS

WITNESS

Dated: _____

Yue Peng

WITNESS

WITNESS

SF 1325467 v1

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**



Title of Invention	DIAGNOSIS AND TREATMENT OF CANCER USING MAMMALIAN PELLINO POLYPEPTIDES AND POLYNUCLEOTIDES
--------------------	--

As the below named inventor(s), I/we declare that:

This declaration is directed to:

The attached application, or
 Application No. 10/041,030 filed on December 28, 2001
 as amended on _____ (if applicable);

RECEIVED

JUN 11 2002

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application, if applicable; and


All statements made herein of my/our own knowledge are true, all statements made herein of information and belief are believed to be true, and further that these statements were made with knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

TECH CENTER 1600/29
RECEIVED
AUG 26 2002

COPY OF PAPERS
ORIGINALLY FILED

FULL NAME OF INVENTOR(S)

Inventor 1 Scott Powers Date: 3/20/02

Signature:  Citizen of: United States

Inventor 2 David Mu Date: 3/20/02

Signature:  Citizen of: Taiwan

Inventor 3 Phil Xiang Date: _____

Signature: _____ Citizen of: United States

Inventor 4 Yue Peng Date: 3/20/02

Signature:  Citizen of: China

Additional inventors are being named on form(s) attached hereto.

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**



Title of Invention	DIAGNOSIS AND TREATMENT OF CANCER USING MAMMALIAN PELLINO POLYPEPTIDES AND POLYNUCLEOTIDES
--------------------	--

As the below named inventor(s), I/we declare that:

This declaration is directed to:

The attached application, or
 Application No. 10/041,030 filed on December 28, 2001
 as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the National or International filing date of the continuation-in-part application, if applicable; and

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor 1 Scott Powers Date: JUN 17 2002

Signature: Citizen of: United States

Inventor 2 David Mu Date: JUN 17 2002

Signature: Citizen of: Taiwan

Inventor 3 Phil Xiang Date: 3/18/02

Signature: Citizen of: United States

Inventor 4 Yue Peng Date: JUN 17 2002

Signature: Citizen of: China

Additional inventors are being named on form(s) attached hereto.

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1156678 v1

RECEIVED

JUN 11 2002

TECH CENTER 1600/290

TECH CENTER 600/290

AUG 26 2002

RECEIVED